Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
John F Seymour, Robert Marcus, Andrew Davies, Eve Gallop-Evans, Andrew Grigg, Andrew Haynes, Michael Herold, Thomas Illmer, Herman Nilsson-Ehle, Martin Soekler, Ulrich Duenzinger, Tina Nielsen, Aino Launonen, Wolfgang Hiddemann
Haematologica | FERRATA STORTI FOUNDATION | Published : 2019
The authors would like to thank all of the patients who participated in the GALLIUM study, and acknowledge all of the study investigators and their staff as well as the GALLIUM study team. Third-party medical writing assistance, under the direction of John Seymour, was provided by Roger Nutter, Scott Malkin and Helen Cathro of Gardiner-Caldwell Communications, and was funded by F. Hoffmann-La Roche Ltd.